HR+ advanced breast cancer

HR+ advanced breast cancer | Advanced prostate cancer | Endometriosis

ZOLADEX for HR+ advanced breast cancer
Practice support and reimbursement resources

ZOLADEX for hormone-receptor-positive (HR+) advanced breast cancer

Consider ZOLADEX for your appropriate patients with HR+ advanced breast cancer. ZOLADEX is a gonadotropin-releasing hormone (GnRH) agonist indicated for use in the palliative treatment of advanced breast cancer in premenopausal and perimenopausal women. The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial. For the management of advanced breast cancer, ZOLADEX is intended for long-term administration unless clinically inappropriate.

ZOLADEX 3.6 mg should be administered subcutaneously every 28 days into the anterior abdominal wall below the navel line, using an aseptic technique. While a delay of a few days is permissible, every effort should be made to adhere to the 28-day schedule. Instructions for proper administration are demonstrated in the administration video.

The most frequently reported adverse reactions were related to hypoestrogenism. The most commonly reported adverse reactions with ZOLADEX in breast cancer clinical trials were hot flashes (70%), decreased libido (47.7%), tumor flare (23%), nausea (11%), edema (5%), and malaise/fatigue/lethargy (5%). Injection site reactions were reported in less than 1% of patients.

Please see additional Important Safety Information below and the full Prescribing Information.

Practice support and reimbursement resources

Learn more about valuable resources for your practice and your patients. TerSera has partnered with eBlu Solutions to provide reimbursement support, and ZOLADEX has its own unique J-Code. Click here to learn more about these services as well as the ZOLADEX Co-pay Card and Patient Assistance Program.


See and share the answers to frequently asked questions about ZOLADEX that patients may ask. These answers can help patients understand what ZOLADEX is, how it works, and what they may expect from therapy with ZOLADEX for HR+ advanced breast cancer. Go to the patient FAQs.


The following list of resources is provided as a convenience to you. TerSera takes no responsibility for the content of, or services provided by, these resources and makes no representation as to the accuracy or completeness of any information provided by these resources. TerSera shall have no liability for any damage or injuries of any kind arising from the information provided by the resources listed. The descriptions of the organizations are all directly from their respective Web sites.

Professional resources to support you

The American Society of Clinical Oncology promotes and provides for lifelong learning for oncology professionals; cancer research; an improved environment for oncology practice; access to quality cancer care; a global network of oncology expertise; and educated and informed patients with cancer. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer.

The National Cancer Institute is part of the National Institutes of Health. The NCI is the federal government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice.

The Agency for Healthcare Research and Quality’s mission is to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and to work within the US. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. AHRQ guidelines for advanced breast cancer are available at:

Resources to help you support your patients

The American Cancer Society is the largest volunteer organization in the United States and is committed to saving lives from cancer by helping people stay well, helping people get well, finding cures, and fighting back against cancer. There are 900 local offices nationwide to deliver lifesaving programs and services at the community level.

This foundation is dedicated to eradicating breast cancer as a life-threatening disease through research, education, screening, and treatment. It raises awareness and funds for breast cancer research with its annual Susan G. Komen Race for the Cure events across the country. Services include a toll-free "helpline" (1-877-GO KOMEN) staffed by trained volunteers. The foundation also funds research and other cancer-related programs.

Young Survival Coalition (YSC) is dedicated to the critical issues unique to young women who are diagnosed with breast cancer. YSC offers resources, connections, and outreach so women feel supported, empowered, and hopeful. YSC offers a broad range of resources and events to support the community of breast cancer survivors and co-survivors (partners, spouses, parents, siblings, friends—anyone who supports you). YSC’s Tour de Pink (TdP) is an inspiring three-day charity bike ride, with a one-day option, that raises funds for young women affected by breast cancer.

The National Cancer Institute is part of the National Institutes of Health. NCI conducts and supports research, training, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. is dedicated to providing information and community to those touched by breast cancer. They are committed to providing complete, accurate, and private breast cancer information.

Breast Cancer Action’s mission is to achieve health justice for all women at risk of and living with breast cancer.

This organization provides current news about breast cancer and relevant clinical research studies through its Web site, patient networking conferences, and interactive teleconferences with experts on a myriad of breast cancer issues. The site also offers empowering stories about women living with breast cancer, as well as message boards.

The Metastatic Breast Cancer Network is dedicated to the unique concerns of the women and men living with metastatic breast cancer, also known as Stage IV or advanced breast cancer. They provide education and information on treatments and on coping with the disease, so those living with advanced breast cancer can be their own best advocate.

The National Breast Cancer Foundation helps women by providing help and inspiring hope to those affected by breast cancer through early detection, education, and support services.

The National Comprehensive Cancer Network is an alliance of 25 of the world’s leading cancer centers. The NCCN is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer.

3170005 Last Updated 9/15

Important Safety Information About ZOLADEX

  • Anaphylactic reactions to ZOLADEX have been reported in the medical literature. ZOLADEX is contraindicated in patients with a known hypersensitivity to GnRH, GnRH agonist analogues, or any of the components in ZOLADEX
  • ZOLADEX is contraindicated during pregnancy unless used for palliative treatment of advanced breast cancer. ZOLADEX can cause fetal harm when administered to a pregnant woman. If used during pregnancy, the patient should be apprised of the potential hazard to the fetus. There is an increased risk for pregnancy loss due to expected hormonal changes that occur with ZOLADEX treatment. ZOLADEX should not be given to women with undiagnosed abnormal vaginal bleeding
  • Pregnancy must be excluded for use in benign gynecological conditions. Women should be advised against becoming pregnant while taking ZOLADEX. Effective nonhormonal contraception must be used by all premenopausal women during ZOLADEX therapy and for 12 weeks following discontinuation of therapy
  • Transient worsening of tumor symptoms, or the occurrence of additional signs and symptoms of breast cancer, may occasionally develop during the first few weeks of treatment. Some patients may experience a temporary increase in bone pain. Monitor patients at risk for complications of tumor flare
  • Hyperglycemia and an increased risk of developing diabetes or worsening of glycemic control in patients with diabetes have been reported in men receiving GnRH agonists like ZOLADEX. Monitor blood glucose levels and glycosylated hemoglobin (HbA1c) periodically and manage according to current clinical practice
  • Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists like ZOLADEX in men. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice
  • Hypercalcemia has been reported in some prostate and breast cancer patients with bone metastases after starting treatment with ZOLADEX. If hypercalcemia does occur, appropriate treatment measures should be initiated
  • Hypersensitivity, antibody formation and acute anaphylactic reactions have been reported with GnRH agonist analogues
  • ZOLADEX may cause an increase in cervical resistance. Therefore, caution is recommended when dilating the cervix for endometrial ablation
  • Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes
  • Injection site injury and vascular injury including pain, hematoma, hemorrhage and hemorrhagic shock, requiring blood transfusions and surgical intervention, have been reported with ZOLADEX. Extra care should be taken when administering ZOLADEX to patients with low BMI and/or to patients receiving full dose anticoagulation
  • Treatment with ZOLADEX may be associated with a reduction in bone mineral density over the course of treatment. Data suggest a possibility of partial reversibility. In women, current available data suggest that recovery of bone loss occurs on cessation of therapy in the majority of patients
  • In women the most frequently reported adverse reactions were related to hypoestrogenism. The adverse reaction profile was similar for women treated for breast cancer, dysfunctional uterine bleeding, and endometriosis
  • The most commonly reported adverse reactions with ZOLADEX in clinical trials for endometriosis were: hot flashes (96%), vaginitis (75%), headache (75%), decreased libido (61%), emotional lability (60%), depression (54%), sweating (45%), acne (42%), breast atrophy (33%), seborrhea (26%), and peripheral edema (21%)
  • The most commonly reported adverse reactions with ZOLADEX in clinical trials for endometrial thinning were: vasodilation/hot flashes (57%), headache (32%), sweating (16%), and abdominal pain (11%)
  • The most commonly reported adverse reactions with ZOLADEX in breast cancer clinical trials were hot flashes (70%), decreased libido (47.7%), tumor flare (23%), nausea (11%), edema (5%), and malaise/fatigue/lethargy (5%). Injection site reactions were reported in less than 1% of patients
  • The most commonly observed adverse reactions during ZOLADEX treatment for prostatic carcinoma were due to the expected physiological effects from decreased testosterone levels. The most common adverse reactions (incidence of >5% in prostate clinical trials) were:
    • For ZOLADEX 3.6-mg: Hot flashes (62%), sexual dysfunction (21%), decreased erections (18%), lower urinary tract symptoms (13%), lethargy (8%), pain (worsened in the first 30 days) (8%), edema (7%), upper respiratory infection (7%), rash (6%), and sweating (6%)
    • For ZOLADEX 10.8-mg: Hot flashes (64%), pain (general) (14%), gynecomastia (8%), pelvic pain (6%), and bone pain (6%)
  • In the locally advanced carcinoma of the prostate clinical trial, additional adverse event data were collected for the combination therapy with radiation group during both the hormonal treatment and hormonal treatment plus radiation phases of this study. Adverse experiences (incidence >5%) in both phases of this study were hot flashes (46%), diarrhea (40%), nausea (9%), and skin rash (8%). Treatment with ZOLADEX and flutamide did not add substantially to the toxicity of radiation treatment alone


  • Management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate in combination with flutamide. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy
  • Palliative treatment of advanced carcinoma of the prostate
  • Management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months
  • Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding
  • Palliative treatment of advanced breast cancer in pre- and perimenopausal women

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit or call 1-800-FDA-1088.

You may also contact TerSera Therapeutics at 1-888-374-6627 or